L3VLUP
ProSign in

ELAN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ELANLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ELAN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterELANLLY
Q3 20206 holders, $2.9bn33 holders, $14.1bn
Q4 202016 holders, $4.1bn29 holders, $17.3bn
Q1 202112 holders, $4.0bn24 holders, $23.0bn
Q2 202114 holders, $4.6bn24 holders, $27.8bn
Q3 202110 holders, $4.0bn31 holders, $29.9bn
Q4 202113 holders, $3.8bn31 holders, $34.7bn
Q1 202211 holders, $3.1bn24 holders, $35.3bn
Q2 202211 holders, $2.4bn33 holders, $42.7bn
Q3 202215 holders, $1.9bn31 holders, $43.4bn
Q4 202215 holders, $1.7bn31 holders, $46.6bn
Q1 202312 holders, $1.2bn33 holders, $44.3bn
Q2 202313 holders, $1.6bn37 holders, $59.6bn
Q3 202312 holders, $1.7bn44 holders, $67.6bn
Q4 20239 holders, $1.9bn45 holders, $73.6bn
Q1 202410 holders, $2.3bn41 holders, $95.3bn
Q2 20249 holders, $2.1bn43 holders, $110bn
Q3 20247 holders, $1.5bn45 holders, $107bn
Q4 20245 holders, $1.5bn46 holders, $93.9bn
Q1 20256 holders, $1.5bn42 holders, $98.4bn
Q2 20259 holders, $2.5bn43 holders, $93.2bn
Q3 202512 holders, $3.4bn39 holders, $86.7bn
Q4 20259 holders, $3.3bn41 holders, $123bn
Q1 20265 holders, $3.0bn39 holders, $106bn
Q2 202610 holders, $3.6bn44 holders, $132bn
ELAN

Elanco Animal Health Inc

Holders
9
Reported value
$2.5bn
Buyers
8
Sellers
2

Breadth +6 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ELAN (0)

None.

Only LLY (34)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Capital Research Global Investors, Coatue Management LLC, D. E. Shaw & Co., Eisler Capital Management Ltd, ExodusPoint Capital Management LP, GAMCO Investors Inc, Harris Associates LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, and 9 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →